ICA-17043
Phase 3Terminated 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Sickle Cell Disease
Conditions
Sickle Cell Disease, Sickle Cell Anemia
Trial Timeline
Feb 1, 2006 → Jun 1, 2007
NCT ID
NCT00294541About ICA-17043
ICA-17043 is a phase 3 stage product being developed by Johnson & Johnson for Sickle Cell Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT00294541. Target conditions include Sickle Cell Disease, Sickle Cell Anemia.
What happened to similar drugs?
4 of 20 similar drugs in Sickle Cell Disease were approved
Approved (4) Terminated (9) Active (8)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00294541 | Phase 3 | Terminated |
Competing Products
20 competing products in Sickle Cell Disease